CHARACTERIZATION OF RELEVANT MOUSE MODELS FOR NEW BIOMARKERS
Vera Niederkofler, Tina Loeffler, Stefanie Flunkert, Agnes Kasza, Ewald Auer, Birgit Hutter-Paier
BEHAVIORAL CHARACTERIZATION OF LOW COPY SOD1 G93A TRANSGENIC MICE
Stefanie Flunkert, Roland Rabl, Agnes Kasza, Vera Niederkofler, Ewald Auer, Birgit Hutter-Paier
RELEVANCE OF CHOICE OF BRAIN REGION AND TIME POINT OF ANALYSIS AFTER MPTP LESIONING IN WILDTYPE MICE
Jan Kehr1,3, Victoria Schiffer2, Shimako Yoshitake1, Tina Loeffler2, Vera Niederkofler2, Stefanie Flunkert2, Ewald Auer2, Takashi Yoshitake3, Birgit Hutter-Paier2
CHARACTERIZATION OF 4L/PS-NA MICE FOR DIFFERENT BIOMARKERS TO MODEL GAUCHER DISEASE
Stefanie Flunkert1, Staffan Schmidt2, Tina Loeffler1, Vera Niederkofler1, Joerg Neddens1, Maria Posch1, Ewald Auer1, Jan Kehr2, Birgit Hutter-Paier1
BIOANALYTICAL MONITORING OF GENE THERAPY TRIALS: METHODOLOGIES FOR PK-PD ASSESSMENT AND PATIENT ELIGIBILITY
Fabrizia Fusetti
Fabrizia Fusetti will be making a presentation during the plenary session in the 02 Auditorium (Innovate) on Friday, November 22nd at 12:10 pm.
DETERMINATION OF MOXIFLOXACIN IN HUMAN PLASMA AND FECES BY LC-MS/MS
Martijn Hilhorst1, Violaine Augustin2, and Robbert Edens1
2Da Volterra
A DRUG-DRUG INTERACTION STUDY TO STUDY THE EFFECTS OF MULTIPLE DOSES OF THE CYP3A4 MODULATORS ITRACRONAZOLE AND RIFAMPIN ON THE SINGLE DOSE PHARMACOKINETICS OF VATIQUINONE
ChauHwei Fu, Peter Dogterom, Donald Burkindine, Thomas Chou, Christie Elliott, Martin Thoolen
A Drug-Drug Interaction Study to Study the Effects of Multiple Doses of the CYP3A4 Modulators Itraconazole and Rifampin on the Single Dose Pharmacokinetics of Vatiquinone
SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF ACT017, AN ANTI-PLATELET GPVI (GLYCOPROTEIN VI) FAB IN HEALTHY VOLUNTEERS
Peter Dogterom, Christine Voors-Pette, Thomas Chou, Laurien Jullien, Kristell Lebozec, Martine Jandrot-Perrus, Gilles Avenard
INFLUENCE OF RIFAMPIN-MEDIATED OATP1B1/1B3 INHIBITION ON THE PHARMACOKINETICS OF CLAZOSENTAN
Peter Dogterom, Pierre-Eric Juif, Christine Voors-Pette, Mike Ufer, Jasper Dingemanse
A DRUG-DRUG INTERACTION STUDY: THE EFFECTS OF MULTIPLE DOSES OF THE CYP3A4 MODULATORS ITRACONAZOLE AND RIFAMPIN ON THE SINGLE DOSE PHARMACOKINETICS OF VATIQUINONE
Peter Dogterom, ChauHwei Fu, Thomas Chou, Thomas Wade, Christie Elliott, Martin Thoolen
BEHAVIORAL CHARACTERIZATION OF HOMOZYGOUS BACHD RATS
Tina Loeffler1, Stephan Kurat1, Adam Horvath1, Stefanie Flunkert1, Hoa Huu Phuc Nguyen2,3, Robert Wronski1, Birgit Hutter-Paier1
TAU PHOSPHORYLATION PROFILE OF HTAU TRANSGENIC MICE
Joerg Neddens, Tina Loeffler, Magdalena Temmel, Irene Schilcher, David Amschl, Birgit Hutter-Paier
CONSTRUCTION OF A TAU SEED-INJECTION MODEL USING HTAU MICE
Shigeru Akasofu1, Jane Gartlon2, Malcolm Roberts2, Ezat Sajedi3, Rohan de Silva3, Tina Loeffler4, Stephan Duller4, Birgit Hutter-Paier4
INNERVATION OF SKIN SAMPLES OF Α-SYNUCLEIN TRANSGENIC MICE: LINE 61, D-LINE, A53T
Joerg Neddens, Estibaliz Etxebarria, Victoria Krivitsch, Birgit Hutter-Paier
UNTANGLING ALZHEIMER´S DISEASE HALLMARKS IN SENSORY SYSTEMS OF RODENT MODELS
Magdalena Temmel1, Meritxell Aguilo Garcia1,2, Tina Loeffler1, Joerg Neddens1, Irati Aiestaran Zelaia1, Vera Niederkofler1, Stefanie Flunkert1 and Birgit Hutter-Paier1
PROGRESSIVE INCREASE OF ALZHEIMER’S DISEASE PATHOLOGY IN 5XFAD TRANSGENIC MICE
Magdalena Temmel, Tina Loeffler, Joerg Neddens, Irene Schilcher, Birgit Hutter-Paier
CHARACTERIZATION OF 4L/PS-NA MICE FOR ENZYME ACTIVITY
Vera Niederkofler1, Ewald Auer1, Victoria Schiffer1, Tina Loeffler1, Joerg Neddens1,Staffan Schmidt2, Jan Kehr2, Birgit Hutter-Paier1
BEHAVIORAL AND HISTOLOGICAL HALLMARKS OF A MUCOPOLYSACCHARIDOSIS TYPE IIIA MOUSE MODEL
Vera Niederkofler1, Ewald Auer1, David Amschl1, Joerg Neddens1, Elisabet Ohlin Sjöström2, Susanne Gustavsson2, Birgit Hutter-Paier1
CBE TREATMENT OF Α-SYNUCLEIN OVEREXPRESSING AND WILDTYPE MICE MODELS GAUCHER DISEASE PATHOLOGY
Vera Niederkofler, Ewald Auer, David Amschl, Joerg Neddens, Birgit Hutter-Paier
A STUDY TO EVALUATE THE PHARMACOKINETICS AND TASTE PROFILE OF A PROTOTYPE ORALLY DISINTEGRATING TABLET FORMULATION FOR MK-0663
Peter Dogterom1, Khalid Abd Elaziz1, Ruben de Jong1, Susan J. Lee2 and Paul Fackler2
2Merck, Sharp & Dohme Corp, a subsidiary of Merck & Co., Inc, Kenilworth, NJ, USA